▲ Peaking
Business
Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approaches
Roche unveils late-stage data showing its experimental MS pill fenebrutinib cuts relapses by 55% as an FDA decision nears.